224 related articles for article (PubMed ID: 29184413)
1. Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.
Menzella F; Galeone C; Lusuardi M; Simonazzi A; Castagnetti C; Ruggiero P; Facciolongo N
Ther Clin Risk Manag; 2017; 13():1489-1493. PubMed ID: 29184413
[TBL] [Abstract][Full Text] [Related]
2. Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports.
Lombardi C; Menzella F; Passalacqua G
Respir Med Case Rep; 2020; 29():100967. PubMed ID: 31799113
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tezepelumab against uncontrolled severe non-type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab.
Kai Y; Suzuki K; Kataoka R; Sato I; Tamaki S; Muro S
Respirol Case Rep; 2024 Mar; 12(3):e01311. PubMed ID: 38420113
[TBL] [Abstract][Full Text] [Related]
4. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
Dedaj R; Unsel L
J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
[TBL] [Abstract][Full Text] [Related]
5. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T
BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
7. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
Davison J; Doe S
Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
[TBL] [Abstract][Full Text] [Related]
8. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
10. Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic.
Langton D; Sha J; Guo S; Sharp J; Banks C; Wang W; Plummer V; Thien F
Respirology; 2020 Dec; 25(12):1243-1249. PubMed ID: 32365431
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the effectiveness of bronchial thermoplasty in patients with severe asthma in the real world two years after bronchial thermoplasty treatment].
Nong Y; Lin JT; Chen X; Long HY; Li HW
Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(22):1730-1735. PubMed ID: 32536095
[No Abstract] [Full Text] [Related]
13. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).
Menzella F; Fontana M; Galeone C; D'Amato M; Canonica GW; Ghidoni G; Capobelli S; Scelfo C; Simonazzi A; Catellani C; Ruggiero P; Facciolongo N
J Asthma Allergy; 2021; 14():1019-1031. PubMed ID: 34413654
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
[TBL] [Abstract][Full Text] [Related]
16. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics of Severe Refractory Asthma Associated with the Effectiveness of Bronchial Thermoplasty.
Minami D; Kayatani H; Sato K; Fujiwara K; Shibayama T; Yonei T; Sato T
Acta Med Okayama; 2019 Apr; 73(2):155-160. PubMed ID: 31015750
[TBL] [Abstract][Full Text] [Related]
18. [Bronchial thermoplasty for asthma treatment].
Çalışkan T; Okutan O; Kartaloğlu Z
Tuberk Toraks; 2018 Jun; 66(2):156-165. PubMed ID: 30246660
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
